Levitz Michael L 4

4 · Anika Therapeutics, Inc. · Filed Mar 10, 2023

Form 4

Period: 2023-03-09

EVP, CFO, Treasurer

Transactions

Tax Payment
Common Stock
2023-03-09$26.91/sh−1,303$35,064→ 23,559 total
Exercise/Conversion
Restricted Stock Unit
2023-03-09−4,439→ 4,438 total
Exercise: $0.00→ Common Stock (4,439 underlying)
Exercise/Conversion
Common Stock
2023-03-09+4,439→ 24,862 total
Award
Restricted Stock Unit
2023-03-09+17,624→ 17,624 total
Exercise: $0.00→ Common Stock (17,624 underlying)
Award
Stock Option (Right to Buy)
2023-03-09+38,475→ 38,475 total
Exercise: $29.60Exp: 2033-03-09→ Common Stock (38,475 underlying)

Footnotes (7)

[F1]Reflects the second vesting installment of Restricted Stock Units (RSUs) granted on March 9, 2021.
[F2]Reflects an aggregate of 1,303 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2023.
[F3]Reflects the closing price of ANIK common stock on March 9, 2023, the trading day on which the vesting of RSUs gave rise to tax withholding obligations.
[F4]Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024.
[F5]Represents a 10% premium above the closing price of Anika's common stock on the date of grant.
[F6]The premium priced stock options vest in three equal annual installments beginning on March 9, 2024.
[F7]Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022.

Documents

1 file